Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process. However, prolonged, inflammation overrides the bounds of physiological control and eventually becomes destructive[@b1]. Inflammation is increasingly seen as a key feature in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and perhaps even neuropsychiatric illness[@b2][@b3][@b4][@b5]. Further, chronic stress may induce transient spinal neuroinflammation, triggering long-lasting anxiety-induced hyperalgesia[@b6]. The reported ability of inflammation-activated signalling pathways in the brain\'s hypothalamus to control the production of ageing related hormones provides a link between inflammation, stress responses and ageing[@b7]. Inflammation thus constitutes an important target for neuronal protection in neurodegenerative disorders and neuropathic pain, the latter resulting from damage or disease affecting the somatosensory system[@b8].

An extensive communication exists between the immune system and the central nervous system (CNS), with inflammatory cytokines occupying a key niche in this network, regulating host responses to infection, inflammation, stress, and trauma. Microglia, the brain\'s principal resident immune cell population are central to the inflammatory response and can be activated by distress signals released from neighbouring cells[@b9]. Microglia that enter a pro-inflammatory state are largely activated by pattern recognition receptors (PRRs), fundamental components of the host innate immunity. PRRs identify pathogen-associated molecular patterns (PAMPs), which are linked with microbial pathogens or cell stress, as well as danger-associated molecular patterns released during cell damage. Toll-like receptors (TLRs) are a subfamily of PRRs abundantly expressed in a number of CNS cell types and, in particular, microglia. To date, 10 functional TLRs have been identified in humans and as many as 12 in mouse[@b10]. Each TLR recognizes a specific array of PAMPs. For example, TLR3 specifically engages double-stranded RNA, indicating a role in host defence against viruses[@b11], whereas TLR2 shows affinity for a wide range of PAMPs originating from bacteria, virues, fungi and parasites[@b12]. TLR4 is triggered not only by lipopolysaccharides (LPS) from Gram-negative bacteria, but also recognizes danger-associated molecular patterns released by injured tissue[@b13][@b14]. Recruitment of TLRs contributes to inflammation by amplifying pro-inflammatory mediator release[@b15][@b16]. In the case of TLR4, a major route of such amplification may be via the purinergic receptor P2X~7~ (P2X~7~R). Interleukin-1β (IL-1β) is now viewed as master regulator of neuroinflammation[@b17]; it makes an important contribution to cellular activation and cytokine production. As such, IL-1β plays a crucial role in the pathogenesis of acute and chronic diseases of both the peripheral nervous system and CNS[@b18][@b19][@b20].

Although LPS is a potent stimulus for IL-1β synthesis, endotoxin-dependent release of the cytokine from microglia is a rather inefficient process with most of the secreted IL-1β in the unprocessed and inactive pro-form[@b21]. However, ATP, via activation of P2X~7~R and caspase 1 within the context of the inflammasome is a powerful stimulus for the secretion of active mature IL-1β. This activation appears to operate as a two-step process: for example, TLR ligands like LPS prime cells (signal 1) by inducing the transcription and translation of IL-1β, followed by a secondary signal such as ATP (signal 2) to trigger formation of the inflammasome complex that leads to caspase 1 activation and cleavage/release of IL-1β[@b22][@b23]. P2X~7~R-triggered IL-1β maturation and export may thus represent a major contributor to this cytokine pool[@b22][@b24]. However, it is not known whether or not this process occurs also across CNS regions and TLR family members. This is an important point, given the reported heterogeneity in activation responses in microglia from different CNS regions[@b25]. The present study was therefore designed to examine the ability of ATP to promote IL-1β release from cortical, spinal cord and cerebellar microglia activated with TLR2, TLR3 and TLR4 agonists, in a P2X~7~R-dependent manner. Because astrocytes may influence the sensitivity of microglia to a priming stimulus[@b26], these experiments were carried out using also both enriched and nominally microglia-free astrocytes.

Results
=======

Microglia from cortex, spinal cord and cerebellum release IL-1β in response to TLR agonists in an ATP-dependent manner
----------------------------------------------------------------------------------------------------------------------

In the brain, IL-1β is mainly produced by activated microglia[@b27]. Although bacterial endotoxin is a potent activator of IL-1β transcription and translation, release of the cytokine is a rather inefficient process[@b21]. ATP, by activating P2X~7~R is a powerful stimulus for secretion of mature IL-1β from microglial cell lines which have undergone a short priming with LPS[@b22][@b27][@b28]. This process occurs in primary cortical microglia, as well[@b26] ([Fig. 1a](#f1){ref-type="fig"}). While not described previously, primary cultures of rat cerebellar microglia ([Fig. 1a](#f1){ref-type="fig"}) and rat spinal cord ([Supplementary Fig. S1a](#s1){ref-type="supplementary-material"}) also release IL-1β in a LPS- and ATP-dependent fashion, thus indicating that cortex does not represent a special case.

P2X~7~R-triggered IL-1β maturation and export may contribute significantly to this cytokine pool in nervous system pathologies[@b22][@b24]. An important question is thus whether or not other TLR ligands are capable of functioning as priming agents. Microglia express functional TLR2[@b29] and TLR3[@b30] in addition to TLR4. TLR signaling pathways may be involved in neurodegenerative disorders[@b31], including motor neuron disease[@b32], cerebral hypoxia-ischemia[@b15][@b16][@b33] and blood-spinal cord barrier dysfunction after ischemia/reperfusion injury[@b34], along with microglial TLR2[@b29] and TLR3[@b30] in preclinical pain models. For these experiments zymosan and Pam3CSK4 (TLR2 activators)[@b35] and poly(I:C), an activator of TLR3[@b36] were used. None of the TLR ligands tested nor ATP treatment alone caused appreciable amounts of IL-1β to accumulate in the culture medium, whilst pretreatment with zymosan, Pam3CSK4 and poly(I:C) followed by ATP challenge resulted in a marked release of IL-1β from cortical ([Fig. 1b--d](#f1){ref-type="fig"}), cerebellar ([Fig. 1b--d](#f1){ref-type="fig"}) and spinal cord ([Supplementary Fig. S1b--d](#s1){ref-type="supplementary-material"}) microglia. The ATP-dependent release of IL-1β in all cases was blocked by the potent and selective P2X~7~R antagonist A740003[@b37] ([Fig. 1](#f1){ref-type="fig"}, [Supplementary Fig. S1](#s1){ref-type="supplementary-material"}).

Stress-activated protein kinase signalling and TLR/ATP-dependent IL-1β release from CNS microglia
-------------------------------------------------------------------------------------------------

The signalling pathway(s) involved in TLR/ATP-dependent IL-1β release from primary CNS microglia was explored using inhibitors for the stress-responsive protein kinases p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK). The p38 inhibitor SB202190 and the JNK inhibitor SP600125 (10 μM each) produced a significant reduction in IL-1β accumulation in the culture medium, independent of microglial cell population and TLR activator used, suggesting a common mechanism of action ([Fig. 1](#f1){ref-type="fig"} and [Supplementary Fig. S1](#s1){ref-type="supplementary-material"}). In contrast, the MAPK kinase inhibitor PD98059 was ineffective (data not shown). Neither SB202190 nor SP600125 prevented the reduction in intracellular IL-1β content resulting from incubation of microglia with TLR ligand followed by ATP (see [Fig. 2](#f2){ref-type="fig"} for examples), indicating that blocking p38 or JNK does not interfere with P2X~7~R action. This is in contrast to the action of the P2X~7~R antagonist A740003, which effectively restored the intracellular pool of IL-1β in TLR ligand/ATP-treated spinal cord ([Fig. 2a](#f2){ref-type="fig"}) and cerebellar ([Fig. 2b](#f2){ref-type="fig"}) microglia -- most likely a consequence of blocking P2X~7~R-dependent cleavage of IL-1β precursor to the releasable mature form. However, effects of SB202190 and SP600125 on IL-1β levels in the culture medium can probably be attributed to their inhibition of IL-1β production intracellularly: in cortical microglia incubated 3 h with zymosan ( = 100%), SB202190 and SP600125 reduced IL-1β content to 18.8 ± 0.3% and 53.7 ± 14.5%, respectively, while the value for zymosan + A740003 was 86.6 ± 8.2% (mean ± s.e.m., n = 3). Using LPS instead, the corresponding intracellular IL-1β values were 34.6 ± 8.7%, 30.0 ± 3.2%, and 86.5 ± 9.3%, respectively, for SB202190, SP600125 and A740003.

Microglia, but not astrocytes produce IL-1β in response to TLR agonists
-----------------------------------------------------------------------

Astrocyte cultures frequently contain minor numbers of contaminating microglia, which can complicate interpretation of responses[@b38], and modify astrocyte responses in some cases[@b39]. Further, pro-inflammatory stimuli can affect the expression of similar genes in microglia and astrocytes[@b38][@b40]. The lysosomotropic agent L-leucyl-L-leucine methyl ester (Leu-Leu-OMe)[@b41] was employed to eradicate residual microglia from the monolayers of enriched astrocytes[@b26][@b42][@b43][@b44]. Under the conditions used, Leu-Leu-OMe does not affect astrocyte vitality[@b26][@b42]. In Leu-Leu-OMe-treated cultures of cortical, spinal cord and cerebellar astrocytes, LPS priming (2 h) followed by a 1-h exposure to ATP failed to elicit release of IL-1β into the medium -- in contrast to the behaviour of parallel astrocyte cultures not treated with Leu-Leu-OMe ([Fig. 3a](#f3){ref-type="fig"}). Analogous results were obtained when the various astrocyte populations were first primed with zymosan ([Fig. 3b](#f3){ref-type="fig"}), Pam3CSK4 ([Fig. 3c](#f3){ref-type="fig"}) or poly(I:C) (data not shown) for 2 h and then exposed to ATP for 1 h. Treatment with Leu-Leu-OMe has been shown efficacious in removing microglia from cortical and spinal cord enriched astrocytes[@b26]. Real-time polymerase chain reaction (RT-PCR) analysis of Leu-Leu-OMe-treated cerebellar astrocytes showed Iba1 gene expression to be 0.81 ± 0.16% (n = 3) of non-treated cells, indicating eradication of this contaminating cell population. Lack of IL-1β release from Leu-Leu-OMe-treated enriched astrocytes was not likely a consequence of interference with the release process. The intracellular accumulation of IL-1β in LPS-only stimulated cultures of enriched astrocytes was also abolished by Leu-Leu-OMe treatment ([Fig. 4b](#f4){ref-type="fig"}), suggesting the removal of an agonist-responsive cell population. The difference in total IL-1β content between the LPS and LPS/ATP groups did not differ significantly ([Fig. 4c](#f4){ref-type="fig"}), indicating that the difference in intracellular IL-1β content between these two groups ([Fig. 4b](#f4){ref-type="fig"}) could be accounted for by release of the cytokine into the culture medium ([Fig. 4a](#f4){ref-type="fig"}).

Previous studies showed that cortical and spinal cord microglia responded to LPS challenge far more robustly in the presence of astrocytes[@b26]. Comparison of [Figure 2a](#f2){ref-type="fig"} (purified cerebellar microglia) with [Figure 3b](#f3){ref-type="fig"} (enriched cerebellar astrocytes) shows IL-1β release from the latter (containing ≤ 5% microglia) which appears to be disproportionate for the numbers of microglia present. To test this, Leu-Leu-OMe-treated cerebellar astrocytes were cultured together with the addition of increasing numbers of cerebellar microglia. Under these conditions the co-cultures displayed a heightened priming response, whereby LPS sensitized the cells to ATP-induced release of IL-1β ([Fig. 5](#f5){ref-type="fig"}, upper panel). Equivalent numbers of microglia alone, however, were essentially devoid of a priming response and IL-1β release ([Fig. 5](#f5){ref-type="fig"}, lower panel).

Earlier studies pointed to a lack of soluble astrocyte-derived factors as being responsible for imparting LPS sensitivity to microglia in terms of mediator release[@b26], suggesting instead a role for physical contact between these two cell populations. This question was examined further using a two-chamber cell culture system, in which an upper layer (insert) of microglia is separated from a lower layer of astrocytes by means of a porous membrane that allows for communication between the compartments. A 24-h LPS incubation of astrocytes only resulted in a very small quantity of IL-1β release ([Table 1](#t1){ref-type="table"}, upper box) but much greater intracellular accumulation, which was reduced by ≥90% following L-LME treatment ([Table 1](#t1){ref-type="table"}, lower box). LPS addition to the microglia compartment also produced a small release of IL-1β but far more intracellularly; interestingly, the presence of LPS in the lower chamber also resulted in IL-1β release by microglia (most likely a result of trans-chamber LPS passage). LPS-treated microglia did not influence IL-1β expression by L-LME-treated astrocytes, either extra- or intracellularly. Although the intracellular content of IL-1β in microglia was greater in the presence of LPS- (and L-LME)-treated astrocytes compared to direct LPS treatment of the microglia (2218 ± 143 and 1407 ± 63 pg, respectively) values for IL-1β release in both cases were similar. Moreover, immunocytochemical analysis of TLR ligand-treated enriched cortical astrocyte cultures showed a lack of coincidence between glial fibrillary acidic protein (GFAP)-positive cells (astrocytes) and IL-1β-immunoreactive cells ([Supplementary Fig. S2](#s1){ref-type="supplementary-material"}).

Discussion
==========

Microglia, the brain\'s resident mononuclear phagocytic cells[@b45] are critical for innate and adaptive responses within the CNS. These immune cells recognize and are activated by various PAMPs, and play a pivotal role in neuroinflammatory processes by releasing a plethora of pro-inflammatory mediators, including IL-1β. As a frontline player in the pathogenesis of acute and chronic inflammatory diseases in the nervous system[@b19], IL-1β stimulates the production of other cytokines, such as IL-6 and IL-8, as well as inducible nitric oxide synthase, chemotactic factors and adhesion molecules, thereby attracting peripheral mononuclear cells to cross the blood-brain barrier[@b46]. Here, we show that ATP-dependent release of IL-1β occurs in microglia (but not astrocytes) cultured from several CNS regions following a priming stimulus with a number of PAMPs, as exemplified by ligands of TLR2, TLR3 and TLR4. The generality of this phenomenon may have important consequences for neuroinflammation and its position to the common pathology of several acute and chronic CNS diseases.

It has been proposed that in multiple chronic disease states, and in ageing, microglia are primed by prior pathology, or by genetic predisposition, to respond more vigorously to subsequent inflammatory stimulation, thus transforming an adaptive CNS inflammatory response to systemic inflammation with deleterious consequences[@b47]. Within this context, the recruitment of TLRs contributes to inflammation by amplifying pro-inflammatory cytokine and other mediator release. TLRs thus play a central role in inflammation\'s impact on neuronal cell health, and their participation in neuroinflammation and neurological diseases is an area of growing interest, encompassing not only acute and chronic neurodegenerative disorders[@b15][@b16][@b32][@b33][@b34][@b48], but also neuropathic pain[@b49] and even mood disorders[@b50]. ATP appears to be one of the most powerful stimuli to enhance and accelerate IL-1β release, via activation of P2X~7~R and caspase 1[@b22][@b23]. Plasma membrane damage or cell death can liberate large amounts of ATP, e.g. following spinal cord injury[@b51]. Further, IL-1β release from the spinal cord dorsal horn upon application of ATP only occurred if preceded by an LPS priming stimulus, and was P2X~7~R-dependent[@b52]. ATP- and P2X~7~R-dependent IL-1β release from endotoxin-primed macrophages and microglial cell lines has been known for some time[@b22], but rarely described in CNS primary microglia (cf. ref. [@b26]). We now show, for the first, that this process occurs in rat primary microglia obtained from cortex, spinal cord and cerebellum, using not only LPS, but also the TLR2 ligand zymosan and Pam3CSK4, and the TLR3 ligand poly(I:C). Zymosan activates macrophages via TLR2, in cooperation with TLR6 and CD14[@b35]. Pam3CSK4, a synthetic triacylated lipopeptide (LP) that mimics the acylated amino terminus of bacterial LPs, is a potent activator of the pro-inflammatory transcription factor nuclear factor-κB[@b53]. Activation is mediated by the interaction between TLR2 and TLR1 which recognizes LPs with three fatty acids, a structural characteristic of bacterial LPs[@b35]. Poly(I:C) is a synthetic analogue of double-stranded RNA, a molecular pattern associated with viral infection and is recognized by TLR3[@b36]. While the TLRs were originally described according to their ability to respond to exogenous microbial products there is sufficient literature to indicate that endogenous products activate TLRs during sterile inflammation. TLR4 recognizes not only LPS, but also ligands called damage associated molecular patterns, released by the injured tissue[@b13][@b14][@b54], while oxidized phospholipid-induced inflammation in macrophages is mediated by TLR2[@b55]. The activation of multiple TLR isoforms in nervous system pathology, coupled with elevated ATP levels in the extracellular milieu and subsequent P2X~7~R activation may represent an important route for microglia-derived IL-1β. Enriched astrocytes and microglia (greater than 93% GFAP-positive and 95% F4/80-positive, respectively) reportedly express also TLR7 and TLR9 (flow cytometry) and respond to TLR7 and TLR9 agonists[@b56], although a microglial contribution to the astrocyte responses was not excluded. Given that TLR7 and/or TLR9 involvement in neuropathic pain and neurodegenerative disease remains open, we focused on TLR2, -3 and -4 in this study.

Nominally microglia-free astrocytes appeared to be devoid of detectable IL-1β induction/release, suggesting either a helper function of microglia to enable astrocytes to produce IL-1β or to microglia themselves as the ultimate source of the cytokine. Although 'clean\' astrocytes were not capable of mounting an IL-1β release (and induction at all) they are a target of IL-1β actions, in development and in responses to injury[@b14][@b56][@b57]. However, using a two-chamber culture system, LPS-stimulated microglia influenced neither IL-1β release nor its intracellular accumulation in purified astrocytes. In addition, culture medium from microglia-depleted, LPS-treated cortical astrocytes was not sufficient to provoke activation of limiting numbers of microglia[@b26]. Further, enriched astrocytes incubated with TLR ligands showed no detectable IL-1β immunoreactivity, in contrast to microglia treated with TLR ligand (see also ref. [@b21]). Our current ([Fig. 5](#f5){ref-type="fig"}) and previous data[@b26] clearly point to an interaction between these two cell populations, as microglia respond more robustly in the presence of astrocytes ([Fig. 5](#f5){ref-type="fig"}; see also ref. [@b26]\]. If astrocytes do not react to TLR stimulation at all, lack of IL-1β production would not be surprising. However, LPS, zymosan and poly(I:C) up-regulate TLR2 mRNA expression in Leu-Leu-OMe-treated astrocytes (Marinelli and Skaper, unpublished observations; see also ref. [@b58] and [@b59]) -- suggesting as well that Leu-Leu-OMe does not compromise astrocyte functionality -- as observed by others[@b42].

The role of stress-responsive kinases in ATP-dependent release of IL-1β from TLR agonist-primed microglia has not been explored. In the present study, release of this cytokine appeared to be sensitive to inhibitors of the stress-activated protein kinases p38 MAPK and JNK. Examination of the intracellular levels of IL-1β, however, revealed that unlike the P2X~7~R antagonist A740003, neither SB202190 nor SP600125 blocked the ATP-dependent reduction in IL-1β content, but rather the intracellular pool of IL-1β induced by TLR agonist per se - indicating that the effects of these kinase inhibitors were not at the level of P2X~7~R.

Astrocytes, the predominant CNS cell type also become reactive following injury and have been implicated in the pathogenesis of CNS inflammation[@b56] and neuropathic pain[@b60]. To the best of our knowledge, release of IL-1β exclusively from this glial cell type, in a TLR and P2X~7~R-dependent fashion, has not been reported. Although astrocytes from cortex, spinal cord and cerebellum released IL-1β following priming with TLR2, -3, or -4 activators and ATP incubation, this response was lost upon depletion of the residual microglia population with Leu-Leu-OMe. Intriguingly, cultures of Leu-Leu-OMe-treated cerebellar astrocytes together with added cerebellar microglia displayed a heightened priming response, whereby LPS sensitized the cells to ATP-induced release of IL-1β. Equivalent numbers of microglia alone, however, were essentially devoid of a priming response and IL-1β release. Similar behaviors have been reported also for cortical and spinal cord glia[@b26], and collectively propose the existence of a 'cross-talk\' pathway between microglia and astrocytes. Such a mechanism in vivo may be an important element in the evolution of an inflammatory pathology, in particular when TLR activation is involved. Together with a growing literature implicating P2X~7~R up-regulation/activation in nervous system pathology[@b24], this route to IL-1β release may provide opportunities for therapeutic intervention in neuroinflammation-associated disorders.

Methods
=======

Materials
---------

Tissue culture media, antibiotics, fetal calf serum (FCS) and NP40 cell lysis buffer (10×) were obtained from Invitrogen (San Giuliano Milanese, Italy); ATP, LPS (Ultra-Pure LPS-EB from *E. coli* 0111:B4 strain), zymosan, Pam3CSK4 (VacciGrade™) and polyinosinic-polycytidylic acid (poly(I:C)) (high molecular weight) were from InvivoGen (Cayla-Invivogen Europe, Toulouse, France); SP600125 was from Calbiochem (Merck Millipore, Milan, Italy); poly-L-lysine hydrobromide (mol wt 70,000--150,000), rat tail type I collagen solution, papain, DNase I (bovine pancreas), trypsin inhibitor, Leu-Leu-OMe, SB202190, protease inhibitor cocktail, Pefabloc® SC (100 mM) and all other biochemicals were purchased from Sigma-Aldrich (Milan, Italy) unless noted otherwise; Falcon tissue culture plasticware and culture well inserts (PET membrane, (0.4 μm pore size, were purchased from BD Biosciences (SACCO srl, Cadorago (CO), Italy). Sterilin petri plastic dishes (10 cm Ø) were from Sarstedt (Verona, Italy).

Primary culture of microglia and astrocytes
-------------------------------------------

Mixed glial cell cultures from cortex and spinal cord were prepared from postnatal day 1--2 rat pups (strain: CD) as previously described[@b61]. Cerebellar tissue dissociates were prepared from 8-day-old pups, using the protocol described for granule neurons[@b62]. Experiments were performed in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals and those of the Italian Ministry of Health (D.L. 116/92), and were approved by the Institutional Animal Care and Use Committee. All tissue dissociates were plated in 75-cm^2^ poly-L-lysine-coated tissue culture flasks at a density of 1.5 brains, 5 spinal cords or 3 cerebella per flask and grown in high-glucose Dulbecco\'s modified Eagle\'s medium (DMEM) with 2 mM glutamine, 100 units/ml penicillin/50 μg/ml streptomycin, 50 μg/ml gentamicin and 10% FCS ('culture medium\'). Medium was changed after 24 h and then twice per week. After 7--10 days microglia were dislodged using an orbital shaker (200 rpm for 1 h, 37°C). Culture supernatants (containing mainly microglia) were transferred to plastic Petri dishes (Sterilin) and incubated for 45 min at 37°C (5% CO~2~, 95% air) to effect differential adhesion of microglia. Adherent microglia (\>99.9% purity, flow cytometric analysis) were mechanically scraped into culture medium and replated in this medium on poly-L-lysine-coated microwell culture plates or dishes. The remaining cell monolayers were highly enriched in astrocytes (\<5% microglia, flow cytometry using cell type-specific antibodies). In some cases astrocytes were depleted of residual microglia using a 60-min exposure (50 mM) to the lysosomotropic agent Leu-Leu-OMe[@b42], as described previously[@b26].

In some cases cell culture inserts were used to establish astrocyte/microglia co-cultures. Enriched astrocytes were seeded into a poly-L-lysine-coated 24-well plate (3 × 10^5^ cells per well) in culture medium. Twenty-four hours later some cultures were treated with 50 mM Leu-Leu-OMe for 60 min, as described above. In parallel, 24-well culture inserts were seeded with 5 × 10^4^ microglia in culture medium (0.4 ml per insert), and placed in a 24-well plate (notched for inserts) in this same medium (0.8 ml/well)[@b63]. Transwell cell culture inserts are convenient, easy-to-use permeable support devices; the suspended design allows for undamaged co-culturing of cells in the lower compartment. The porous transwell membrane allows for communication between the chambers, and for passage of microglia-derived factors to the lower chamber containing astrocytes and vice versa. The following day, inserts were transferred to the 24-well plate of astrocytes. The distance between the astrocyte monolayer and microglia on the insert membrane is 1 mm, according to the manufacturer\'s description. At this time LPS (100 ng/ml final) was added to either the upper or lower chamber (0.4 ml and 0.8 ml final volume, respectively), and incubation continued for another 24 h. The culture medium was then collected, and cells lysed, as described below. The IL-1β content of culture supernatants and lysates was determined by ELISA, as described below.

RT-PCR
------

Cerebellar astrocytes were seeded in poly-lysine-coated 24-well plates at a density of 250,000 cells per well, using culture medium and allowed to adhere overnight. Cells were then incubated with 50 mM Leu-Leu-OMe for 1 h, and then replaced with fresh culture medium. Twenty-four hours later total RNA was extracted from cells by TRIzol (Invitrogen), according to the manufacturer\'s instructions. RNA integrity and quantity were determined by RNA 6000 Nano assay in an Agilent BioAnalyser. RT was performed with Superscript III reverse transcriptase (Invitrogen). The Real-time RT-PCR reaction was performed as described previously[@b26]. The following primer pairs were used:

[GAPDH]{.ul}, 5′-CAAGGTCATCCATGACAACTTTG-3′ F and 5′-GGGCCATCCACAGTCTTCTG-3′ R (89 bp);

[Iba1]{.ul}, 5′-AACTGGAGGCCTTCAAGACG-3′ F and 5′-AACCCCAAGTTTCTCCAGCA-3′ R (101 bp).

Amounts of each gene product were calculated using linear regression analysis from standard curves, demonstrating amplification efficiencies ranging from 90 to 100%. Dissociation curves were generated for each primer pair, showing single product amplification.

Immunofluorescence
------------------

Enriched cortical astrocytes were cultured on poly-L-lysine-coated 8-well chamber slides (Labtek) and incubated the following day with 10 ng/ml LPS for 24 h. The cells were then fixed with 4% paraformaldehyde for 30 min at 4°C, and washed 4 × 5 min with PBS/0.05% Triton X-100, and blocked with PBS/10% FCS for 1 h at room temperature. The cells were then processed for immunostaining with primary antibodies against the microglial marker F4/80 antigen[@b64] (Abcam ab6640, rat monoclonal, 1:500), the astrocyte marker GFAP (Abcam ab7260, rabbit polyclonal, 1:800), or IL-1β (rabbit polyclonal, 1:250, sc7884, Santa Cruz Biotechnology). The IL-1β antibody used detects both the pro- and mature forms of the cytokine. Cells were then washed 5 × 5 min with PBS, and incubated for 1 h at room temperature with anti-mouse-AlexaFluor555 (red) or anti-rabbit-AlexaFluor488 (green) secondary antibody (1:500, Invitrogen). Chamber slides were mounted beneath glass slides using Fluoromount-G (Southern Biotech, USA), and images were acquired on a Leica DMI4000 B microscope equipped for immunofluorescence (Leica Microsystems GmbH, Wetzlar, Germany) using a Leica DFC 480 digital camera.

IL-1β production and release
----------------------------

Microglia and astrocytes were plated in 96-well plates (poly-L-lysine coated; collagen for spinal cord astrocytes) at a density of 100,000 or 50,000 cells per well, respectively, using culture medium and allowed to adhere overnight. These plating densities do not affect glial cell vitality/function[@b66][@b65]. Cells were primed by pre-treating with 1 μg/ml LPS[@b21][@b28] or other TLR ligands as indicated (optimal concentration of TLR activator chosen from preliminary experiments) for 2 h in serum-free culture medium prior to stimulation with 5 mM ATP[@b28] for 1 h. Neither the TLR ligands used nor ATP affected cell viability. It should be pointed out that commercial sources of LPS are frequently contaminated by other bacterial components, such as lipoproteins, capable of activating both TLR2 and TLR4. The Ultra-Pure LPS-EB preparation used here only activates TLR4 (InvivoGen). None of the TLR ligands or ATP, at the concentrations tested, affected cell viability (data not shown; see also ref. [@b58]). Cell supernatants were collected and stored at −20°C until the day of assay (avoiding repeated freeze-thaw cycles). Cell lysates were prepared by adding to each 96-well culture 100 μl lysis solution containing: 89 μl NP40 lysis buffer, 10 μl of 10× protease inhibitor cocktail and 1 μl of 100 mM Pefabloc SC. IL-1β content of culture medium and cell lysates was analyzed using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer\'s instructions (Antigenix America, Huntington Station, NY, USA). The IL-1β ELISA assay kit does not distinguish between the inactive 33-kDa precursor (pro-IL-1β) and the bioactive 17-kDa mature form (as is the case for all commercially available kits). Standards with known amounts of IL-1β were used to convert values into absolute concentrations of IL-1β in pg/ml.

Statistics
----------

Data are given as mean ± SEM. Statistical analyses to determine group differences were performed either by two-sample equal variance Student\'s *t* test, or by one-way analysis of variance, followed by Dunnett\'s or Bonferroni\'s post-hoc tests for comparisons involving more than two data groups. Significance was taken at p \< 0.05.
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![Extracellular ATP causes release of IL-1β from purified rat cortical and cerebellar microglia primed with TLR2, TLR3 and TLR4 ligands.\
Cortical (solid bars) or cerebellar (hashed bars) microglia cultured in 96 well plates were pretreated for 30 min with 10 μM SB202190 ('SB\'), 10 μM SP600125 ('SP\') or 10 μM A740003, followed by a 2-h incubation with: (a) 1 μg/ml LPS for TLR4; (b) 10 μg/ml zymosan ('Zym\') or (c) 0.3 μg/ml Pam3CSK4 ('Pam\') for TLR2; (d) 50 μg/ml poly(I:C) ('P\') for TLR3. ATP was then added to a final concentration of 5 mM. After a further 60 min incubation culture medium was collected for IL-1β analysis by ELISA. Note the different scales used on the y-axes; poly(I:C) appeared to be the least efficacious of the TLR ligands tested. Each indicated treatment group applies to both cell populations. Data are means ± s.e.m. (n = 3). \*\*\*p \< 0.001 and °°°p \< 0.001 vs TLR activator/ATP group for cortical and cerebellar microglia, respectively. Similar results were obtained in two other experiments.](srep06824-f1){#f1}

![A740003, but not SB202190 or SP600125 prevents the ATP-dependent fall in intracellular IL-1β in TLR agonist-primed rat spinal cord and cerebellar microglia.\
Spinal cord (a) and cerebellar (b) microglia cultured in 96 well plates were pretreated for 30 min with 10 μM SB202190 ('SB\'), 10 μM SP600125 ('SP\') or 10 μM A740003 ('A74\'), followed by a 2-h incubation with 10 μg/ml zymosan (a) or 1 μg/ml LPS (b). ATP was then added to a final concentration of 5 mM. After a further 60 min cell lysates were prepared for IL-1β analysis by ELISA. Data are means ± s.e.m. (n = 3). \*\*p \< 0.01 vs zymosan + ATP; \*\*\*p \< 0.001 vs LPS + ATP.](srep06824-f2){#f2}

![L-leucyl-L-leucine methyl ester abolishes IL-1β release triggered by LPS, zymosan and Pam3CSK4 plus ATP from enriched cortical, spinal cord and cerebellar astrocytes.\
Enriched cortical (solid bars), spinal cord (shaded bars) and cerebellar (hatched bars) astrocytes cultured in a 96 well plate were treated with 50 mM L-leucyl-L-leucine methyl ester (L-LME) for 60 min, and returned to fresh culture medium for 24 h. The cultures were then incubated in serum-free medium for 2 h with: (a) 1 μg/ml LPS, (b) 10 μg/ml zymosan, or (c) 0.3 μg/ml Pam3CSK4, each followed by addition of 5 mM ATP. After a further 60 min incubation culture medium was collected for IL-1β analysis. Data are means ± s.e.m. (n = 3). Arrows indicate that a given treatment applies to all three cell populations. In some cases no bar is visible, as the IL-1β was below the limit of detection.](srep06824-f3){#f3}

![Extracellular and intracellular IL-1β content derived from enriched cortical astrocytes incubated with LPS ± ATP.\
Enriched cortical astrocytes cultured in a 96 well plate were incubated in serum-free medium with 1 μg/ml LPS for 2 h followed by addition of 5 mM ATP or not. After a further 60 min incubation culture medium (a) and cell lysates (b) were collected for IL-1β analysis. In some cases cells and prior to LPS/ATP challenge, cells were treated the previous day with 50 mM Leu-Leu-OMe (L-LME) for 60 min, and returned to fresh culture medium for 24 h. Panel (c) presents the sum values for intracellular + extracellular IL-1β. Total IL-1β content for LPS and LPS/ATP did not differ significantly, indicating that the reduced intracellular content for LPS/ATP (panel B) could be accounted for by that released into the culture medium (panel A). Production of the ATP-dependent component of IL-1β was prevented by inclusion of the selective P2X~7~R antagonist A-740003 (not shown). Data are means ± s.e.m. (n = 3).](srep06824-f4){#f4}

![Cerebellar microglia display a heightened LPS sensitization to ATP-induced release of IL-1β in the presence of Leu-Leu-OMe-treated cerebellar astrocytes.\
Upper panel: Enriched cerebellar astrocytes (50 × 10^3^) cultured in a 96 well plate were treated with 50 mM Leu-Leu-OMe (5th - 12th columns) for 60 min, and returned to fresh culture medium for 24 h. After this time the indicated numbers of purified cerebellar microglia were added to the microglia-depleted astrocyte cultures and incubation continued for a further 24 h. The cultures were then incubated in serum-free medium with 1 μg/ml LPS for 2 h followed by addition of ATP to a final concentration of 5 mM. After a further 60 min incubation culture medium was collected for IL-1β analysis. Lower panel: The same numbers of microglia were cultured in a parallel plate, treated with LPS and ATP as above and medium analyzed for IL-1β content. Data are means ± s.e.m. (n = 3).](srep06824-f5){#f5}

###### LPS-stimulated microglia do not increase IL-1β production by astrocytes: a two-chamber model

  IL-1β Release (pg/chamber)                                         
  ---------------------------- ------- ---------- -------- --------- --------
  Insert                         LPS    No L-LME   +L-LME   Control    LPS
  **−**                         **−**    0 ± 0     0 ± 0     \-\--    \-\--
  **−**                         **+**    63 ± 5    0 ± 6     \-\--    \-\--
  **+**                         **−**    \-\--     0 ± 0     0 ± 0    \-\--
  **+**                         **−**    \-\--     0 ± 0     \-\--    30 ± 2
  **+**                         **+**    \-\--     0 ± 0    34 ± 4    \-\--

  Intracellular IL-1β (pg/chamber)                                               
  ---------------------------------- ------- ----------- ---------- ------------ -----------
  Insert                               LPS    No L-LME     +L-LME     Control        LPS
  **−**                               **−**   148 ± 30    169 ± 53     \-\--        \-\--
  **−**                               **+**   1447 ± 42   140 ± 8      \-\--        \-\--
  **+**                               **−**     \-\--     133 ± 9      0 ± 0        \-\--
  **+**                               **−**     \-\--     158 ± 13     \-\--      1407 ± 63
  **+**                               **+**     \-\--     146 ± 24   2218 ± 143     \-\--
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Cortical astrocytes (300 × 10^3^/well) were seeded in a 24-well plate ('lower chamber\') and treated 24 h later with 50 mM L-leucyl-L-leucine methyl ester (L-LME) for 60 min, as indicated. The following day inserts containing cortical microglia (50 × 10^3^/insert) ('upper chamber\') were transferred to the astrocyte-containing wells, as indicated. LPS (100 ng/ml final) was added to either chamber as indicated. Following a further 24-h incubation culture medium and cell lysates were collected and analysed for IL-1β by ELISA. The 24 h incubation time was chosen to maximise signal amplitude. See Methods for full details. Values are means ± s.e.m. (n = 3).
